TVARDI THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
TVARDI THERAPEUTICS, INC. (TVRD) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $335.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $335.00K, a 46.57% decline year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $370.00K, a 362.50% increase year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $339.00K, a 323.75% increase year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $627.00K, a 693.67% increase year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $1.40M, a 338.56% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $319.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $335.00K 10-Q · filed 2026-08-14 | $705.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $370.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $1.40M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $339.00K 10-Q · filed 2025-11-13 | $966.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.05M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $627.00K 10-Q · filed 2026-08-14 | $707.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $80.00K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $319.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $80.00K 10-Q · filed 2025-11-13 | $159.00K derived: sum of 2 quarters · filed 2025-11-13 | $240.00K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $79.00K 10-Q · filed 2025-11-13 | $160.00K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $81.00K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |